Collaborate With Us

Programs

PRODUCT

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

Diabetology Oral Programs: Clinical Progress

Capsulin™ Oral Insulin OAD*

Preparing for Phase 3

Capsulin™ Oral Insulin IR**

12-week study in completion

Oraglutide™ Oral Weekly GLP1 RA

12-week study commenced

Satietyde™: Microdosing Daily Oraglutide for Dropouts and Maintenance Therapy

Preparing for Phase 2 based on Oraglutide data

Oral Fusion GIP/GLP1 Once Weekly POC

IVGTT Human Proof of Concept study

Capsuglutide™: Capsulin™ / Oraglutide™ combination

Preparing for clinic

Capsulin™ / small molecule

Tested in animal models

Oral GLP-1 / GIP combination

Preparing for animal studies

Oral GLP-1 / Gut hormone combination

Preparing for animal studies

Oral Obesity Triagonist peptides

Preparing for animal studies

Potentional Oral Delivery of Third-party Therapeutics (API)

Oral delivery of marketed macromolecules

Oral delivery of development macromolecules

Potentional combination therapies

* OAD is Oral Anti Diabetic agent for treatment of T2DM – improves glycaemic control and compliance and reduces side effects
** IR is an Oral Insulin Replacement for treatment of T1DM – reduces insulinaemia and improves glycaemic control

Capsulin ™

Treatment of Type 2 diabetes mellitus
LEARN MORE

Oral GLP-1

Treatment of Type 2 diabetes mellitus
LEARN MORE

Diabetes Epidemic

12-13% of global population (OECD)
LEARN MORE

Obesity

6% of global population (OECD)

LEARN MORE
STAY UP TO DATE

Get our latest insights and project announcements

Subscribe now

DIABETOLOGY

Oral Capsule Technology for Insulin, GLP-1 and Other Protein-Based Therapies and Combinations.

HEADQUARTERS:
23/27 Seaton place,
Charter Place, St Helier,
Jersey JE1 1JY,
Channel Islands

The London BioScience Innovation Centre
2 Royal College Street, London, NW1 0NH
United Kingdom

Quick Links

Stay in Touch

Copyright © 2026 Diabetology Ltd. All rights reserved.

Get in Touch